statistiche ricercatore

Continente	#
AS - Asia	785
NA - Nord America	549
EU - Europa	255
SA - Sud America	142
AF - Africa	28
Continente sconosciuto - Info sul continente non disponibili	1
OC - Oceania	1
Totale	1.761

Nazione	#
US - Stati Uniti d'America	512
CN - Cina	267
SG - Singapore	223
VN - Vietnam	121
BR - Brasile	104
IT - Italia	90
HK - Hong Kong	42
KR - Corea	40
GB - Regno Unito	32
RU - Federazione Russa	23
FR - Francia	22
SE - Svezia	21
IN - India	20
AR - Argentina	19
MX - Messico	19
NL - Olanda	17
CA - Canada	13
DE - Germania	13
ZA - Sudafrica	13
PL - Polonia	12
TR - Turchia	12
ID - Indonesia	10
JP - Giappone	9
EC - Ecuador	8
IQ - Iraq	8
BD - Bangladesh	6
CO - Colombia	6
FI - Finlandia	6
UA - Ucraina	5
UZ - Uzbekistan	4
AE - Emirati Arabi Uniti	3
DZ - Algeria	3
EG - Egitto	3
HR - Croazia	3
IL - Israele	3
MA - Marocco	3
PK - Pakistan	3
SA - Arabia Saudita	3
AT - Austria	2
AZ - Azerbaigian	2
CH - Svizzera	2
CL - Cile	2
GR - Grecia	2
MY - Malesia	2
PA - Panama	2
PE - Perù	2
RO - Romania	2
TN - Tunisia	2
AU - Australia	1
CI - Costa d'Avorio	1
CR - Costa Rica	1
ES - Italia	1
ET - Etiopia	1
JO - Giordania	1
KE - Kenya	1
KG - Kirghizistan	1
KW - Kuwait	1
KZ - Kazakistan	1
LB - Libano	1
LT - Lituania	1
NI - Nicaragua	1
PH - Filippine	1
PT - Portogallo	1
SN - Senegal	1
SR - Suriname	1
SV - El Salvador	1
SY - Repubblica araba siriana	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.761

Nome	#
Patient derived organoids are an useful tool to investigate Hippo pathway involvement in lung cancer	168
The long non-coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1 transcription factor and activation of Ephrin signaling	154
Harnessing NK Cell Potential Against NSCLC	137
Implementing an organoid platform to assess efficacy of PHD inhibitors as anti-cancer agents	137
Dissecting the role of lncRNAs in promoting Natural Killer cytotoxicity in Non-Small Cell Lung Cancer models	135
PHD2 (EGLN1) is a novel therapeutic target in KRAS-mutated lung carcinoma	135
LncRNA TAZ-AS202 promotes lung cancer progression through the regulation of the E2F1 transcription factor	127
A Two-Step Protocol for Isolation and Maintenance of Lung Cancer Primary 3D Cultures	104
Exploring EGLN1/PHD2 role in KRAS mutated lung cancer: insights into mitochondrial modulation and therapeutic opportunities	101
Unraveling NK Cell-Mediated Cytotoxicity in NSCLC	95
Harnessing the hypoxia pathway to set a new therapeutic strategy for KRAS-mutated lung adenocarcinoma	95
Targeting EGLN1 to Overcome Drug Resistance in KRAS-Mutant Lung Adenocarcinoma: A Patient-Derived Organoid Study	84
Leveraging NK Cell Potential Against NSCLC: insights from long-non coding RNAs	84
null	83
Characterization of EGLN1 as a pro-oncogenic factor and pharmacological target in lung cancer	83
Exploring EGLN1 as a therapeutic target for KRAS mutated lung cancer	61
Totale	1.783

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2024/2025	365	0	19	17	24	62	46	44	22	43	15	39	34
2025/2026	1.418	74	92	196	245	215	70	181	62	141	74	50	18
Totale													1.783